Is Novavax, Inc. (NVAX) a good stock to buy?

Olyth's institutional analysis of NVAX reveals an Altman Z-Score of -2.05 and a Piotroski F-Score of 5/9. These metrics, combined with its 5-year revenue trend ($1.12B most recent), help investors decide if NVAX fits their risk profile.

What is the current P/E ratio for NVAX?

As of the latest trading session, Novavax, Inc. (NVAX) has a trailing P/E ratio of 2.93.

Who is the CEO of Novavax, Inc.?

The current Chief Executive Officer of Novavax, Inc. is John Charles Jacobs.

What was NVAX's revenue for the last 5 years?

According to its latest income statements, Novavax, Inc. reported annual revenues of $1.12B (2025), $0.68B (2024), $0.56B (2023), $1.60B (2022), $0.20B (2021) respectively.

Does NVAX pay a dividend?

Novavax, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does NVAX have?

In its latest reporting period, Novavax, Inc. generated $-0.25B in Free Cash Flow against a total debt load of $0.25B.

What is the Price-to-Book (P/B) ratio of Novavax, Inc.?

The Price-to-Book (P/B) ratio for Novavax, Inc. (NVAX) is currently -10.11.

What is the Price-to-Sales (P/S) ratio of NVAX?

Based on trailing twelve-month data, Novavax, Inc. (NVAX) trades at a Price-to-Sales (P/S) ratio of 1.16.

What is Novavax, Inc.'s Return on Equity (ROE)?

Novavax, Inc. (NVAX) has a Return on Equity (ROE) of -546.21%, representing its profitability relative to shareholder equity.

NVAX

Novavax, Inc. · Healthcare

7.97

3.51%(+0.27)

Prev. Close

8.02

0.63%(+0.05)

Pre-market

Last Updated: — ET

52W L: $5.0152W H: $11.97

$7.94

CHG-1.76 (-18.14%)

H$11.05

L$7.57

VOL66M

NVAX (1h)

Company Profile

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Sector

Healthcare

Industry

Biotechnology

Employees

952

IPO Date

1995-12-05

Beta

2.65

Websitewww.novavax.com↗

NVAX

Traders Purchase Large Volume of Novavax Call Options (NASDAQ:NVAX)

Novavax (NVAX) Stock Dips While Market Gains: Key Facts

Novavax (NASDAQ:NVAX) Stock Price Passes Above 200 Day Moving Average – Here’s Why

3 Companies Built Their Fortunes on COVID Vaccines, but Only 1 Has a Real Plan for What Comes Next

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development